Email Alert | RSS

Journal of Tuberculosis and Lung Health ›› 2018, Vol. 7 ›› Issue (2): 114-119.doi: 10.3969/j.issn.2095-3755.2018.02.008

• Original Articles • Previous Articles     Next Articles

Clinical efficacy analysis of Qingfei Qulao Pill in the treatment of patients with relapsed pulmonary tuberculosis

Li-hua ZHENG(),Jing-lai YU,Peng SUN,Hong-qing LI,Dong CHEN,Ying-jie YU,Sha NI,Ming XU,Yan CHENG,Chun-guang MA,Chun-yu ZHAO,Na YANG,Gui-jiao LI,Juan. LI   

  1. Third Treatment Area of Internal Medicine, Tuberculosis Hospital of Jilin Province, Changchun 130500,China
  • Received:2018-05-03 Online:2018-06-15 Published:2018-08-02

Abstract:

Objective To analyze the clinical efficacy of Qingfei Qulao Pill in treating relapsed pulmonary tuberculosis (PTB).Methods From January to June 2017, relapsed bacterial positive PTB patients in the Tuberculosis Hospital of Jilin Province were randomly selected according to their different treatment methods: 60 cases who received chemical drugs (2H-R-E-Z-S/6H-R-E) combined with Qingfei Qulao Pill were selected as the observation group, while 60 cases who received chemical drugs were selected as the control group. The improvement of clinical symptoms, clinical efficacy, bacterial negative conversion rate, and chest X-ray findings in the two groups were compared.Results All patients in both group completed 8 months of treatment. After treatment, the improvement of clinical symptoms such as fatigue and night sweat in the observation group (the incidences were 10.0% (6/60) and 8.3% (5/60), respectively) were better than that in the control group (75.0% (45/60) and 61.7% (37/60), respectively); the differences were statistically significant (χ 2 values were 51.87 and 37.51; P values were <0.001 and <0.001, respectively). The rate of sputum negative conversion was higher in the observation group (88.3%, 53/60) compared with the control group (76.7%, 46/60), but the difference was not statistically significant (χ 2=2.83, P=0.093). The observation group showed higher treatment efficacy than the control group (88.3% (53/60) vs 76.7% (46/60)), the difference was not statistically significant (Z=-1.71, P=0.088). The findings of Chest X-ray examination showed that the lesions and cavities were significantly absorbed in 43 cases and absorbed in 12 cases in the observation group, yielding an absorbing rate of 91.7% (55/60). The rate was obviously higher than that of the control group (78.3% (47/60); lesions and cavities were significantly absorbed in 26 cases and absorbed in 21 cases); the difference was statistically significant (Z=-3.20, P=0.001). Conclusion Qingfei Qulao Pill can be used as the adjuvant treatment for relapsed PTB, having a good effect on the improvement of clinical symptoms and induction of lesions and cavities absorption.

Key words: Tuberculosis, pulmonary, Retreatment, Antibiotics, antitubercular, Drugs, Chinese herbal, Drug therapy, combination, Treatment outcome